Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gsk Plc ADR
(NY:
GSK
)
36.88
+0.12 (+0.33%)
Official Closing Price
Updated: 7:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gsk Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
...
35
36
Next >
Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's Presser
January 31, 2024
The record run of the market faces risk as the big tech earnings season got off to a negative start, casting cloud on profit outlook.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%
January 30, 2024
Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions.
Via
Benzinga
Elegen and GSK Sign Collaboration and Licensing Agreement to Further Develop Elegen’s Cell-Free DNA Production Technology
January 24, 2024
From
Elegen
Via
Business Wire
What the Options Market Tells Us About GSK
January 09, 2024
Via
Benzinga
GSK's Jemperli Cancer Drug Hits Primary Goal In Endometrial Cancer Study
December 18, 2023
GSK plc (NYSE: GSK)
Via
Benzinga
Earnings Scheduled For January 31, 2024
January 31, 2024
Companies Reporting Before The Bell • Novartis (NYSE:NVS) is likely to report quarterly earnings at $1.68 per share on revenue of $11.56 billion.
Via
Benzinga
Recap: GSK Q4 Earnings
January 31, 2024
Via
Benzinga
Earnings Outlook For GSK
January 30, 2024
Via
Benzinga
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
January 29, 2024
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
A Look Into GSK Inc's Price Over Earnings
January 26, 2024
Via
Benzinga
Looking Into GSK's Recent Short Interest
December 18, 2023
Via
Benzinga
GSK Cuts More Stake In Its Spun-Off Consumer-Healthcare Business Haleon, Raises Over £900M
January 17, 2024
GSK sells 300M shares in Haleon at £326/share, raising £978M. GSK to retain 4.2% stake.
Via
Benzinga
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
January 13, 2024
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will...
Via
Talk Markets
Pfizer's Aggressive Stance In Obesity Drugs: CEO Albert Bourla Confirms Bold Bet Despite Prior Drug Hurdles
January 09, 2024
Monday, at the JP Morgan Healthcare Conference, Pfizer Inc (NYSE: PFE) CEO Albert Bourla expressed that the company is determined to move forward in the burgeoning
Via
Benzinga
GSK Boosts Its Asthma Product Portfolio With Over $1B Deal For Aiolos Bio
January 09, 2024
GSK plc (NYSE: GSK) has agreed to acquire Aiolos Bio Inc
Via
Benzinga
GSK Enters Agreement to Acquire Aiolos Bio
January 09, 2024
From
Aiolos Bio, Inc.
Via
Business Wire
GlaxoSmithKline PLC (NYSE: GSK) Records 52-Week High Monday Morning
January 08, 2024
Via
Investor Brand Network
Strides Toward Lower Drug Costs: Florida Becomes First To Receive Nod To Import Prescription Drugs from Canada
January 05, 2024
The FDA has allowed Florida to import prescription drugs from Canada, potentially altering the landscape of how Americans access and afford their medications.
Via
Benzinga
Exposures
Product Safety
Why Biopharmaceutical Player CureVac Shares Are Rising Today
January 05, 2024
CureVac N.V. (NASDAQ: CVAC) shares are trading higher on Friday.
Via
Benzinga
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
Sleeper Hits: 3 Unexpected Stocks Poised for a Breakout in 2024
January 05, 2024
Many stocks emerge from Wall Street's doghouse relatively quickly. Here are three names that could become surprise breakout stocks for 2024.
Via
InvestorPlace
More Than 140 Drug Brands Will Have Their Prices Hiked Heading Into 2024
January 04, 2024
More than 140 brands of drugs are going to see their prices hiked heading into the new year
Via
Talk Markets
Dell To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Wednesday
January 03, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Verona Pharma's Promising COPD Treatment Puts It in GSK's Acquisition Crosshairs, Analysts Predict Big Moves
December 29, 2023
In recent statements to the Financial Times and The Sunday Times, GSK plc (NYSE: GSK) Chief Commercial Officer Luke Miels revealed the company's intent to pursue acquisitions within the $2 billion...
Via
Benzinga
Expensive Drugs For Americans In 2024? Drugmakers Including Pfizer, Sanofi Mull Price Increase In January
December 29, 2023
Just as large pharma companies prepare a showdown with Medicare's newfound power to negotiate down drug prices, several major drug companies are reportedly gearing up to implement price increases on...
Via
Benzinga
Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024
December 28, 2023
2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations.
Via
Benzinga
3 Growth at a Reasonable Price (GARP) Stocks for Balanced Growth
December 22, 2023
GARP stocks are less likely to plunge than growth stocks with high valuations and more likely to generate strong growth than value stocks.
Via
InvestorPlace
Merck's Chronic Cough Treatment Candidate Receives Second Time FDA Rejection
December 21, 2023
The FDA issued a Complete Response Letter (CRL) regarding Merck & Co Inc's (NYSE: MRK) New Drug Application (NDA) for gefapixant under development for the treatment of refractory chronic cough (RCC) or...
Via
Benzinga
Exposures
Product Safety
COVAX Global Initiative For COVID-19 Vaccines Comes To An End Amid Shift To Regular Programs
December 20, 2023
COVAX, the multilateral mechanism for equitable global access to COVID-19 vaccines launched in 2020, will close on 31 December 2023.&n
Via
Benzinga
Exposures
COVID-19
GSK Awards $1M in COiMMUNITY Initiative Grants to Support Adult Immunization and Health Equity
December 12, 2023
From
GSK plc
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
35
36
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.